145. ウエスト症候群 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 49 / 薬物数 : 43 - (DrugBank : 16) / 標的遺伝子数 : 29 - 標的パスウェイ数 : 28

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
18 FDG
   National Institute of Neurological Disorders and Stroke (NINDS)
      1992   -   NCT00001325   United States
Acth
   All India Institute of Medical Sciences, New Delhi
      2022   Phase 2/Phase 3   NCT05279118   India
   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
      2021   -   ChiCTR2100053371   China
   Wayne State University
      2013   Phase 4   NCT02092883   United States
Acth/oral steroids
   All India Institute of Medical Sciences, New Delhi
      2024   Phase 2/Phase 3   NCT06201897   India
Adrenocorticotropin hormone
   Ann & Robert H Lurie Children's Hospital of Chicago
      2011   -   NCT01367964   United States
AMZ002
   Amzell B.V
      2023   Phase 3   EUCTR2021-003015-26-IT   France;Italy;Poland;Spain;United States
   Amzell B.V.
      2022   Phase 3   EUCTR2021-003015-26-ES   France;Poland;Spain;United States
      -   Phase 3   EUCTR2021-003015-26-FR   France;Germany;Poland;Spain;United States
Cannabidiol
   GW Research Ltd
      -   Phase 3   EUCTR2015-004904-50-PL   Hungary;Italy;Poland;United Kingdom;United States
Cannabidiol oral solution
   Benuvia Therapeutics Inc.
      2018   Phase 3   NCT03421496   United States
CBD
   GW Research Ltd
      -   Phase 3   EUCTR2015-004904-50-PL   Hungary;Italy;Poland;United Kingdom;United States
Combination therapy with vigabatrin and prednisolone
   Kullasate Sakpichaisakul
      2020   -   NCT04302116   Thailand
Cosyntropin injectable suspension 1 MG/ML + vigabatrin
   University of Colorado, Denver
      2018   Phase 3   NCT03347526   United States
Cosyntropin injectable suspension, 1 MG/ML
   University of Colorado, Denver
      2018   Phase 3   NCT03347526   United States
Decortin H
   Royal United Hospital Bath NHS Trust
      2010   Phase 4   EUCTR2006-000788-27-DE   Australia;Germany;New Zealand;Switzerland;United Kingdom
Exome and/or whole genome sequencing
   Boston Children's Hospital
      2010   -   NCT01858285   United States
Famotidine
   University of California, Los Angeles
      2025   Phase 2   NCT06819670   United States
Fenfluramine
   Children's Hospital of Orange County
      2023   Phase 2   NCT04289467   United States
Ganaxolone
   Marinus Pharmaceuticals
      2007   Phase 2   NCT00442104   United States
      2007   Phase 2   NCT00441896   United States
   Marinus Pharmaceuticals, Inc.
      2007   -   EUCTR2006-004285-13-CZ   Czech Republic
   Marinus Pharmceuticals, Inc.
      2007   -   EUCTR2006-004286-33-CZ   Czech Republic
      -   Phase 2   EUCTR2006-004286-33-PL   Czech Republic;Poland
GWP42003-P
   GW Research Ltd
      -   Phase 3   EUCTR2015-004904-50-PL   Hungary;Italy;Poland;United Kingdom;United States
   Jazz Pharmaceuticals
      2017   Phase 3   NCT02954887   Poland;United States
      2017   Phase 3   NCT02953548   Poland;United States
Intravenous methylprednisolone
   Suvasini Sharma
      2019   Phase 2/Phase 3   NCT03876444   India
Jbpos0101
   Bio-Pharm Solutions Co., Ltd.
      2020   Phase 2   NCT03976076   Korea, Republic of;United States
Ketogenic diet
   All India Institute of Medical Sciences, New Delhi
      2022   Phase 2/Phase 3   NCT05279118   India
M071754
   Alfresa Pharma Corporation
      2014   Phase 4   JPRN-jRCT2080222508   -
      2014   Phase 3   JPRN-jRCT2080222507   -
   Alfresa Pharma Corporation and Sanofi KK
      -   Phase 3   EUCTR2017-000611-17-Outside-EU/EEA   Japan
      -   Phase 3   EUCTR2017-000230-62-Outside-EU/EEA   Japan
Melatonin
   Department of Pediatrics, The First Medical Center, General Hospital of the People's Liberation Army of China
      2020   Phase 0   ChiCTR2000036208   China
Modified atkins diet
   All India Institute of Medical Sciences, New Delhi
      2009   Phase 2/Phase 3   NCT01006811   India
Oral pednisolone
   Suvasini Sharma
      2019   Phase 2/Phase 3   NCT03876444   India
Oral prednisolone
   Lady Hardinge Medical College
      2012   Phase 3   NCT01575639   India
Prednisolone
   Royal United Hospital Bath NHS Trust
      2010   Phase 4   EUCTR2006-000788-27-DE   Australia;Germany;New Zealand;Switzerland;United Kingdom
   The Hospital for Sick Children
      2017   Phase 3   NCT02299115   Canada
   University of California, Los Angeles
      2025   Phase 2   NCT06819670   United States
Prednisone
   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
      2021   -   ChiCTR2100053371   China
Pyridoxine plus prednisolone
   Lady Hardinge Medical College
      2012   Phase 3   NCT01828437   India
Radiprodil
   UCB Biopharma S.P.R.L.
      2017   Phase 2   NCT02829827   Belgium;Bulgaria;France;Germany;United Kingdom
   UCB Biopharma SPRL
      2017   Phase 2   EUCTR2016-002107-26-FR   Belgium;Bulgaria;France;Germany;United Kingdom
      2017   Phase 2   EUCTR2016-002107-26-DE   Belgium;Bulgaria;France;Germany;United Kingdom
      2017   Phase 2   EUCTR2016-002107-26-BG   Belgium;Bulgaria;France;Germany;United Kingdom
      2016   Phase 2   EUCTR2016-002107-26-GB   Belgium;Bulgaria;France;Germany;United Kingdom
      2016   Phase 2   EUCTR2016-002107-26-BE   Belgium;Bulgaria;France;Germany;United Kingdom
Sabril
   Amzell B.V
      2023   Phase 3   EUCTR2021-003015-26-IT   France;Italy;Poland;Spain;United States
   Amzell B.V.
      2022   Phase 3   EUCTR2021-003015-26-ES   France;Poland;Spain;United States
      -   Phase 3   EUCTR2021-003015-26-FR   France;Germany;Poland;Spain;United States
   Lundbeck LLC
      2009   -   NCT01073579   -
   Orphelia Pharma
      2014   -   NCT02220114   France
   Royal United Hospital Bath NHS Trust
      2010   Phase 4   EUCTR2006-000788-27-DE   Australia;Germany;New Zealand;Switzerland;United Kingdom
Sabril granules FOR oral USE
   TARGEON
      -   Phase 2   EUCTR2014-000360-17-FR   France
Sabril sachets
   Royal United Hospital Bath NHS Trust
      2006   Phase 4   EUCTR2006-000788-27-GB   Germany;United Kingdom
Sabrilex
   Kirsi Mikkonen/Helsinki University Hospital
      2018   Phase 4   EUCTR2017-004775-30-FI   Finland
Soluble prednisolone tablets
   Royal United Hospital Bath NHS Trust
      2006   Phase 4   EUCTR2006-000788-27-GB   Germany;United Kingdom
SPT3162
   Marinus Pharmceuticals, Inc.
      2007   -   EUCTR2006-004286-33-CZ   Czech Republic
      -   Phase 2   EUCTR2006-004286-33-PL   Czech Republic;Poland
Synacthen depot
   Royal United Hospital Bath NHS Trust
      2010   Phase 4   EUCTR2006-000788-27-DE   Australia;Germany;New Zealand;Switzerland;United Kingdom
      2006   Phase 4   EUCTR2006-000788-27-GB   Germany;United Kingdom
Tetracosactide acetate
   Royal United Hospital Bath NHS Trust
      2010   Phase 4   EUCTR2006-000788-27-DE   Australia;Germany;New Zealand;Switzerland;United Kingdom
      2006   Phase 4   EUCTR2006-000788-27-GB   Germany;United Kingdom
Tricaprilin
   Cerecin
      2021   Phase 1   NCT04727970   Australia;Singapore
UCB3491
   UCB Biopharma SPRL
      2017   Phase 2   EUCTR2016-002107-26-FR   Belgium;Bulgaria;France;Germany;United Kingdom
      2017   Phase 2   EUCTR2016-002107-26-DE   Belgium;Bulgaria;France;Germany;United Kingdom
      2017   Phase 2   EUCTR2016-002107-26-BG   Belgium;Bulgaria;France;Germany;United Kingdom
      2016   Phase 2   EUCTR2016-002107-26-GB   Belgium;Bulgaria;France;Germany;United Kingdom
      2016   Phase 2   EUCTR2016-002107-26-BE   Belgium;Bulgaria;France;Germany;United Kingdom
VGB-ST soluble tablets
   TARGEON
      -   Phase 2   EUCTR2014-000360-17-FR   France
Vigabatrin
   Alfresa Pharma Corporation
      2014   Phase 4   JPRN-jRCT2080222508   -
      2014   Phase 3   JPRN-jRCT2080222507   -
   Alfresa Pharma Corporation and Sanofi KK
      -   Phase 3   EUCTR2017-000611-17-Outside-EU/EEA   Japan
      -   Phase 3   EUCTR2017-000230-62-Outside-EU/EEA   Japan
   Amzell B.V
      2023   Phase 3   EUCTR2021-003015-26-IT   France;Italy;Poland;Spain;United States
   Amzell B.V.
      2022   Phase 3   EUCTR2021-003015-26-ES   France;Poland;Spain;United States
      -   Phase 3   EUCTR2021-003015-26-FR   France;Germany;Poland;Spain;United States
   Benuvia Therapeutics Inc.
      2018   Phase 3   NCT03421496   United States
   Kirsi Mikkonen/Helsinki University Hospital
      2018   Phase 4   EUCTR2017-004775-30-FI   Finland
   Lundbeck LLC
      2012   Phase 4   NCT01413711   -
   Orphelia Pharma
      2014   -   NCT02220114   France
   Royal United Hospital Bath NHS Trust
      2010   Phase 4   EUCTR2006-000788-27-DE   Australia;Germany;New Zealand;Switzerland;United Kingdom
      2006   Phase 4   EUCTR2006-000788-27-GB   Germany;United Kingdom
   TARGEON
      -   Phase 2   EUCTR2014-000360-17-FR   France
   The Hospital for Sick Children
      2017   Phase 3   NCT02299115   Canada
Vigabatrin tablets
   Kullasate Sakpichaisakul
      2020   -   NCT04302116   Thailand
Vitamin B1
   Faculty of Pediatrics, the first Medical Centre, Chinese PLA General Hospital
      2021   Phase 0   ChiCTR2100045702   China